Sino Biological CDH17 Recombinant Human Protein, His Tag
This recombinant protein was expressed from a DNA sequence encoding the human CDH17 (Q12864-1) extracellular domain (Met 1-Met 787) fused to a polyhistidine tag at the C-terminus
Manufacturer: Invitrogen 11360H08H5
DescriptionCadherin 17, LI cadherin (liver-intestine) (CDH17), recombinant human protein is supplied as a lyophilized powder. It is suitable for use in analysis of protein structure, and performing cell based assays. It can also be used as an immunogen, as a protein standard, or in other research applications.
- Activity: Measured by the ability of the immobilized protein to support the adhesion of MCF-7 human breast adenocarcinoma cells; when 5 x 104 cells/well are added to recombinant human Cadherin 17 coated plates (0.8µg/mL with 100µL/well), approximately >50% will adhere after 1 hour at 37°C
- Formulation: Lyophilized in 140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4, 5% Mannitol, 5% Trehalose, 0.02% Tween 80
- Reconstitution: Dissolve the protein in sterile double distilled water to a concentration of 0.2mg/mL or lower; aliquot and use as soon as possible
|Proteins, Expression, Isolation & Analysis; Enzyme & Protein Activity Assays; Protein Assay Controls, Reference Standards & Accessories|
|Intercellular Adhesion Molecule|
|CDH16, FLJ26931, HPT-1, HPT1, mgC138218, mgC142024|
|Cell Structure/Organelle Proteins|
|≥85% by SDS-PAGE|
|Store at -20°C. Store aliquots under sterile conditions at -20°C. Avoid repeated freeze-thaw cycles. Expires one year from date of receipt when stored as instructed.|
|Cadherin 17, LI cadherin (liver-intestine)|
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok